Olaparib Temozolomide
Olaparib Temozolomide - Related Videos
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
0 Views •
Cited by 17 •
2015
The lymphodepletive and immunomodulatory effects of chemotherapy and radiation standard of care can be leveraged to enhance the antitumor efficacy of T cell immunotherapy. We outline a method for generating EGFRvIII-specific chimeric antigen receptor (CAR) T cells and administering them in the context of glioblastoma standard of care.
03:17
Cellular Bioluminescence Based Assay: A High Throughput Method for Combinatorial Drug Screening
0 Views •
2023
In this video, we describe a method highlighting the utility of bioluminescence assay for sensitive and rapid screening of drugs. These drugs can be tested alone or in combination to assess the synergism in their mode of action.
08:50
Use of Cerebral Open-Flow Microperfusion for the Longitudinal Collection of Interstitial Fluid in an Animal Model of Glioblastoma
0 Views •
2025
In vivo, intercellular communications underpinning many central nervous system diseases, such as glioblastoma (GBM), are notoriously difficult to measure and characterize. Here, we describe procedures of cerebral open-flow microperfusion (cOFM) that can be employed to sample interstitial fluid components in a longitudinal animal model of GBM.
09:26
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
0 Views •
Cited by 8 •
2011
Here, we established a method for drug efficacy testing with surgical specimens of brain tumors, termed “tumor explant method”. With this method, we can evaluate drug efficacy without breaking the microenvironment of solid tumors. To validate reliability of this method, we describe representative data with our glioma specimen treated with the current first-line chemotherapeutic agent, temozolomide.
FAQs
The two agents affect connected stages of DNA damage handling. Temozolomide creates methylated DNA bases, while olaparib prevents PARP-mediated repair of resulting single-strand breaks. During DNA replication, unrepaired lesions can progress into double-strand breaks, which are more damaging to tumor cells. This complementary activity may produce enhanced cytotoxicity when repair capacity is already limited.
Olaparib can do more than inhibit PARP repair activity: it can trap PARP on damaged DNA. The trapped protein may obstruct processing of lesions and increase the persistence or severity of DNA damage generated by temozolomide. This mechanism helps explain why the combination may intensify stress on tumor cells beyond the effect of blocking single-strand break repair alone.
Response depends on several interacting variables rather than on drug pairing alone. Tumor genotype can influence DNA-repair capacity, while the extent of drug exposure affects how much damage accumulates. Toxicity can also limit treatment intensity and alter the achievable exposure. Consequently, the same combination may produce different antitumor effects across tumor types or experimental models.
Investigators study the strategy in both preclinical models and clinical trials. Preclinical work can examine how tumor cells or models respond to the combined DNA damage, whereas clinical studies assess whether those findings translate into antitumor activity in patients. Together, these settings support evaluation of treatment effects, response patterns, and limitations associated with toxicity.
Research can determine whether combining the agents produces greater antitumor activity than expected from their separate actions. Studies also seek to identify cancers that respond particularly well and to clarify how tumor genotype, drug exposure, and toxicity shape outcomes. These findings may guide efforts to improve treatment outcomes and select more suitable research populations.
Tumor genotype can indicate whether a cancer has limited DNA-repair capacity, a feature that may increase vulnerability to accumulated damage from the combination. Because the treatment relies on stressing repair processes, genetically different tumors may not respond uniformly. Evaluating genotype alongside drug exposure and toxicity helps researchers interpret variable activity and investigate which cancers are most responsive.